TLRY · Tilray Brands, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 2, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Dec 2, 2025.
Up next
AI Brief
Q4 FY26 earnings call · Jul 28, 2026TL;DR. Tilray delivered record fiscal 2026 revenue of $915 million and record adjusted EBITDA of $61.1 million while reducing net debt to $0.7 million, and guided to $68–$75 million in fiscal 2027 adjusted EBITDA reflecting double-digit growth, with international medical cannabis revenue up 34% and the BrewDog acquisition creating a roughly $500 million global beverage platform.
- + Fiscal 2027 adjusted EBITDA guidance of $68–$75 million, reflecting double-digit growth new
- + International medical cannabis revenue grew 34% in fiscal 2026 new
- + BrewDog acquisition created a roughly $500 million pro forma global beverage platform new
- + Net debt reduced to $0.7 million, a 95% year-over-year improvement, with ~$235 million in cash and marketable securities new
- + Carlsberg partnership and Carlsberg beer production to begin January 1 new
- − CEO expressed disappointment in stock performance and absence of shareholder rewards new
- − BrewDog required nearly $50 million of incremental working capital shortly after a ~$54 million acquisition new
- − European cannabis experienced major price compression during the year new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $63.4M | fiscal 2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 29% | fiscal 2026 | — |
| Adjusted net income non-GAAP | $12.2M | fiscal 2026 | — |
| Adjusted net income (loss) per share - basic non-GAAP | $0.11 | For the year ended May 31, 2026 | — |
| Adjusted net income per share non-GAAP | $0.11 | fiscal 2026 | — |
| Cannabis adjusted gross margin (excluding PPA step-up) non-GAAP | 40% | For the year ended May 31, 2026 | — |
|
|
|||
| Cash flow from operations, excluding working capital | $18.2M | fiscal year ended May 31, 2026 | — |
| Cash, restricted cash and Marketable Securities non-GAAP | $235M | fiscal year ended May 31, 2026 | — |
| Net Debt non-GAAP | $0.7M | fiscal year ended May 31, 2026 | — |
| Wellness gross margin | 33% | For the year ended May 31, 2026 | — |
|
|
|||
| Adjusted cash operating income (loss) non-GAAP | $17.75M | the nine months ended February 28, 2026 | — |
|
|
|||
| Adjusted free cash flow non-GAAP | -$42.64M | the nine months ended February 28, 2026 | — |
|
|
|||
| Adjusted gross profit non-GAAP | $174.55M | the nine months ended February 28, 2025 | — |
| Adjusted net income (loss) non-GAAP | $4.4M | the nine months ended February 28, 2026 | — |
|
|
|||
| Adjusted net income (loss) per share non-GAAP | $0.02 | Q3 Fiscal 2026 | — |
| Free cash flow non-GAAP | -$52.86M | the nine months ended February 28, 2026 | — |
|
|
|||
| Net cash position non-GAAP | $3.5M | Q3 Fiscal 2026 | — |
|
|
|||
| Adjusted gross profit (excluding PPA step-up) non-GAAP | 57.5M | For the three months ended November 30, 2025 | — |
| Cash and marketable securities non-GAAP | $291.6M | the second quarter | — |
| Cash and marketable securities as at the period ended | 291.55M | For the three months ended November 30, 2025 | — |
| Distribution gross margin non-GAAP | 13% | For the three months ended November 30, 2025 | — |
| Working capital as at the period ended | 470M | For the three months ended November 30, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TLRY
this stock
Tilray Brands, Inc.
|
$625.17M | -49.4% | +11.5% | — | 13.5% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +15.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.38B | -0.1% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.46B | -0.8% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Dec 2, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TLRY | -3.2% | -1.5% | -36.5% | +0.7% | -49.4% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -3.7% | -2.8% | -49.8% | -2.0% | -61.9% |